VC-backed Forty Seven unveils IPO
Menlo Park, California-based Forty Seven, a clinical stage immuno-oncology company, has debuted its IPO after pricing its over 7 million shares at $16 per share. The stock began trading June 28, 2018 on the NASDAQ under the ticker symbol "FTSV." Morgan Stanley and Credit Suisse are the lead underwriters. Forty Seven's pre-IPO backers include Wellington Management Company LLP, Clarus, Lightspeed Venture Partners, Sutter Hill Ventures and GV.
28 June 2018•2 mins read
